Key result
Biomedicus centrifugal pump support for cardiogenic shock yields survival reaching ~47% depending on etiology.
Why the study?
Experience and outcomes of mechanical circulatory support using the Biomedicus centrifugal pump in patients with cardiogenic shock were evaluated over seven years.
Cohort (n=61)
Mechanical circulatory support with a centrifugal pump in cardiogenic shock yields modest survival rates, with better outcomes in postcardiotomy shock compared to post-MI or other etiologies, but is limited by high rates of bleeding and multiorgan failure.
Answers are grounded in this paper and cite their sources.
Centrifugal pump support yields modest, etiology-dependent survival in cardiogenic shock; leaves open optimal device selection without randomized evidence.
From September 1987 to September 1994 61 patients between 29 and 78 years of age received mechanical circulatory support by means of the Biomedicus centrifugal pump. The patients were divided into three groups by indication: Group I included 15 patients with early postcardiotomy cardiogenic shock and 24 patients with late postcardiotomy cardiogenic shock. Group II 11 patients with therapy-resistant cardiogenic shock following acute myocardial infarction, and Group III 11 patients with cardiogenic shock of other etiologies. Duration of support was 1 to 347 hours. Survival rates were 46.7% and 33.3% in patients with early and late postcardiotomy cardiogenic shock, respectively (Group I), 27.2% in Group II, and 18.1% in Group III. Most frequent complications were bleeding (40%, 58%) and acute renal failure (26.7%, 29.2%) in Group I and multiple organ failure in Groups II and III (64% and 45.5%). Major causes of death were bleeding and multiple organ failure in Group I (37.5%) and multiple organ failure in Groups II and III (87.5% and 50%). Groups II and III (87.5% and 50%).
No takes yet. Share an insight, caveat, or question.
El‐Banayosy et al. (1995) conducted a cohort in Cardiogenic shock (n=61). Biomedicus centrifugal pump was evaluated on Survival. Mechanical circulatory support with the Biomedicus centrifugal pump for cardiogenic shock resulted in survival rates ranging from 18.1% to 46.7% depending on the etiology.
Synapse has enriched 10 related papers. Consider them for comparative context: